The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB
The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB
WHO has recommended that multidrug-resistant tuberculosis (MDR-TB, defined as resistance to
 at least isoniazid (H) and rifampicin (R) be addressed as a public health crisis and enhance
 capacity to deliver effective treatment and care. According to the 2018 WHO TB Report, the
 overall treatment success rate of MDR-TB is 55% while much lower in China at just only 41%
 with the 24-month regimen. In order to further verify the safety and efficiency of optimizing
 shorter 18-month regimen containing 6 anti-TB drugs with MDR-TB patients,500 more patients
 will be enrolled and observed.
1. Design: the study is a multi-center,open, single arm trial.

 2. Population:patients with sputum culture positive and confirmed as MDR-TB via drug
 resistance of isoniazid(H),rifampicin(R),ethambutol(E)and pyrazinamide or patients with
 GeneXpert confirmed RR-TB.

 3. Investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are
 the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated
 drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium
 para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The
 abbreviation of the name of the 3 drugs in the regimen is explained as follows:
 PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is
 18 months.

 4. Primary and secondary outcome measures:

 The primary outcome measures include 1.the treatment success rate.2. Death rate.

 The secondary outcome measures include 1.sputum conversion rate at the end of month 2,
 month 3,intensive phase of 6 months and treatment completion of all enrolled
 patients.2.Frequency of adverse drug reaction occurring during treatment.3.Radiological
 manifestation change of TB lesion or cavity during treatment.

 5. Sample size: 500 eligible patients will be enrolled.
Inclusion Criteria:

 -  Is willing and able to give informed consent to participate in the trial treatment and
 follow-up.

 -  Is aged between 18 years and 70 years.

 -  Has a positive sputum culture result or a positive GeneXpert result.

 -  Has evidence of RR-TB or MDR-TB either by GeneXpert or culture-based drug
 susceptibility testing (DST).

 -  Non pre-XDR-TB or XDR-TB.

 -  Is willing to use effective contraception of women at childbearing age.

 -  Has had a chest X-ray that is compatible with a diagnosis of pulmonary TB.

 Exclusion Criteria:

 -  pre-XDR-TB or XDR-TB.

 -  Has a known allergy to any drug of the regimen.

 -  Is currently taking or took part in another trial less than three months before the
 study initiation .

 -  Is HIV positive.

 -  Has abnormal ECG with QT prolongation over 430ms of men while 450 of women.

 -  Is critically ill, and in the judgment of the investigator, unlikely to take part in
 the study.Or has any condition (social or medical) which in the opinion of the
 investigator would make study participation unsafe.

 -  Is known to be pregnant or breast-feeding.

 -  Has severe cardiovascular diseases, such as heart failure, hypertension (poor blood
 pressure control), arrhythmia or post-infarction status.

 -  Has severe concomitant severe disease such as respiratory failure or cardiac
 insufficiency or liver and kidney injury with aspartate aminotransferase (AST) or
 alanine aminotransferase (ALT) more than 2.5 times the upper limit of normal or with
 serum creatinine(Cr)more than 1.3 times the upper limit of normal.

 -  Has Karnofsky score less than 50%